Mi­croR­NA play­er Mi­Ra­gen bags $40M round and a pub­lic stock list­ing in re­verse merg­er

Boul­der, CO-based Mi­Ra­gen Ther­a­peu­tics has found its way in­to the pub­lic mar­kets, re­verse merg­ing with strug­gling Sig­nal Ge­net­ics and gain­ing a $40 mil­lion round to fi­nance its next stage of de­vel­op­ment.

The mi­croR­NA biotech had com­plet­ed an­oth­er $40 mil­lion crossover round last fall, just as the mar­ket was shriv­el­ing for high-risk biotech plays. Its new syn­di­cate in­cludes Fi­deli­ty Man­age­ment and Re­search Com­pa­ny, Brace Phar­ma Cap­i­tal, At­las Ven­ture, Boul­der Ven­tures, JAF­CO Co., Ltd., MP Health­care Ven­ture Man­age­ment, MRL Ven­tures (Mer­ck), Remedi­tex Ven­tures, and oth­ers.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.